

# Antonio Rosato

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4915734/antonio-rosato-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167  
papers

8,738  
citations

42  
h-index

91  
g-index

191  
ext. papers

10,189  
ext. citations

8  
avg, IF

5.65  
L-index

#	Paper	IF	Citations
167	Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 830710	8.4	4
166	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020.. <i>Cancer Immunology, Immunotherapy</i> , <b>2022</b> , 1	7.4	
165	Design, Synthesis and Preclinical Assessment of Tc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging.. <i>Molecules</i> , <b>2022</b> , 27,	4.8	3
164	Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance.. <i>Nature Cell Biology</i> , <b>2022</b> , 24, 168-180	23.4	5
163	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	
162	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	6
161	Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. <i>Cellular and Molecular Immunology</i> , <b>2021</b> , 18, 1197-1210	15.4	2
160	Clinical Efficacy and Safety of Angiogenesis Inhibitors: Sex Differences and Current Challenges. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	4
159	Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis. <i>Diabetes</i> , <b>2021</b> , 70, 1767-1779	0.9	4
158	The immune cell landscape of metastatic uveal melanoma correlates with overall survival. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 154	12.8	4
157	Preclinical dosimetric studies of Lu-scFvD2B and comparison with Lu-PSMA-617 and Lu-iPSMA endoradiotherapeutic agents. <i>Medical Physics</i> , <b>2021</b> , 48, 4064-4074	4.4	0
156	Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma. <i>Nature Cancer</i> , <b>2021</b> , 2, 174-188	15.4	23
155	PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB "Super-Stimulation". <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 708073	5.3	1
154	Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	30
153	Development of Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen. <i>Scientific Reports</i> , <b>2020</b> , 10, 9313	4.9	5
152	Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. <i>Oncotarget</i> , <b>2020</b> , 9, 1777046	7.2	3
151	Reprogramming normal cells into tumour precursors requires ECM stiffness and oncogene-mediated changes of cell mechanical properties. <i>Nature Materials</i> , <b>2020</b> , 19, 797-806	27	70

150	Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 579894	8.4	1
149	A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks. <i>Cytotherapy</i> , <b>2020</b> , 22, 511-518	4.8	1
148	Labelled micelles for the delivery of cytotoxic Cu(II) and Ru(III) compounds in the treatment of aggressive orphan cancers: Design and biological in vitro data. <i>Journal of Inorganic Biochemistry</i> , <b>2020</b> , 213, 111259	4.2	5
147	Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. <i>Nature Communications</i> , <b>2020</b> , 11, 3945	17.4	26
146	162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial. <i>Annals of Oncology</i> , <b>2020</b> , 31, S304-S305	10.3	6
145	Preliminary dosimetric analysis of DOTA-folate radiopharmaceutical radiolabelled with Sc produced through V(p,x)Sc cyclotron irradiation. <i>Physics in Medicine and Biology</i> , <b>2020</b> ,	3.8	1
144	Real-Time Label-Free Targeting Assessment and in Vitro Characterization of Curcumin-Loaded Poly-lactic-glycolic Acid Nanoparticles for Oral Colon Targeting. <i>ACS Omega</i> , <b>2019</b> , 4, 16878-16890	3.9	9
143	Internal radiation dose assessment of radiopharmaceuticals prepared with cyclotron-produced Tc. <i>Medical Physics</i> , <b>2019</b> , 46, 1437-1446	4.4	8
142	A non-covalent antibody complex for the delivery of anti-cancer drugs. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2019</b> , 142, 49-60	5.7	2
141	Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2019</b> , 34, 1131-1139	5.6	5
140	Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway. <i>Diabetes</i> , <b>2019</b> , 68, 1303-1314	0.9	33
139	Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis. <i>Nature Cell Biology</i> , <b>2018</b> , 20, 28-35	23.4	67
138	Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells. <i>Cell Death and Differentiation</i> , <b>2018</b> , 25, 1224-1238	12.7	23
137	Enhancing Cytokine-Induced Killer (CIK) cell activity with Her2-specific Fc-engineered antibodies and antibody derivatives. <i>European Journal of Cancer</i> , <b>2018</b> , 92, S23-S24	7.5	2
136	Radioisotopic purity and imaging properties of cyclotron-produced Tc using direct Mo(p,2n) reaction. <i>Physics in Medicine and Biology</i> , <b>2018</b> , 63, 185021	3.8	11
135	[Tc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of $\alpha_5\beta_1$ Integrin: Synthesis, Structure-Activity and Pharmacokinetic Studies. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 9596-9610	8.3	11
134	BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. <i>Cell Death and Differentiation</i> , <b>2018</b> , 25, 1808-1822	12.7	16
133	Glucocorticoid receptor signalling activates YAP in breast cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 14073	7.4	89

132	Design, synthesis and evaluation of biotin decorated inulin-based polymeric micelles as long-circulating nanocarriers for targeted drug delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2017</b> , 13, 1245-1254	6	36
131	Re-programming pullulan for targeting and controlled release of doxorubicin to the hepatocellular carcinoma cells. <i>European Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 103, 104-115	5.1	23
130	A BARP1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. <i>Oncolmunology</i> , <b>2017</b> , 6, e1304338	7.2	9
129	Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. <i>Cytokine and Growth Factor Reviews</i> , <b>2017</b> , 36, 99-105	17.9	26
128	A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. <i>Nature Communications</i> , <b>2017</b> , 8, 15772	17.4	66
127	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. <i>Oncolmunology</i> , <b>2017</b> , 6, e1313371	7.2	7
126	Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide. <i>Advanced Healthcare Materials</i> , <b>2017</b> , 6, 1700596	10.1	32
125	Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4 T Cells. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 197	8.4	18
124	Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. <i>BioMed Research International</i> , <b>2017</b> , 2017, 5791262	3	15
123	The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis. <i>Oncotarget</i> , <b>2017</b> , 8, 15520-15538	3.3	13
122	Thiol-Activated Anticancer Agents: The State of the Art. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2017</b> , 17, 4-20	2.2	4
121	Drug and protein delivery by polymer conjugation. <i>Journal of Drug Delivery Science and Technology</i> , <b>2016</b> , 32, 132-141	4.5	28
120	Human IgGs induce synthesis and secretion of IgGs and neonatal Fc receptor in human umbilical vein endothelial cells. <i>Immunobiology</i> , <b>2016</b> , 221, 1329-1342	3.4	4
119	Induction of Expandable Tissue-Specific Stem/Progenitor Cells through Transient Expression of YAP/TAZ. <i>Cell Stem Cell</i> , <b>2016</b> , 19, 725-737	18	142
118	Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. <i>Oncolmunology</i> , <b>2016</b> , 5, e1199311	7.2	15
117	Site-Specific Transglutaminase-Mediated Conjugation of Interferon $\beta$ at Glutamine or Lysine Residues. <i>Bioconjugate Chemistry</i> , <b>2016</b> , 27, 2695-2706	6.3	33
116	Site-selective enzymatic chemistry for polymer conjugation to protein lysine residues: PEGylation of G-CSF at lysine-41. <i>Polymer Chemistry</i> , <b>2016</b> , 7, 6545-6553	4.9	22
115	Fast method for skeletal tissue gene expression analysis. <i>Biomedical Reports</i> , <b>2016</b> , 5, 248-250	1.8	1

114	Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. <i>Nature Cell Biology</i> , <b>2016</b> , 18, 897-909	23.4	142
113	Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. <i>Cancer Research</i> , <b>2016</b> , 76, 4775-84	10.1	40
112	Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 431-40	12.5	16
111	Improvement of diaphragmatic performance through orthotopic application of decellularized extracellular matrix patch. <i>Biomaterials</i> , <b>2016</b> , 74, 245-55	15.6	45
110	Thiol-Activated Anticancer Agents: The State Of The Art. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2016</b> , 16, 1-1	2.2	12
109	A site-selective hyaluronan-interferon $\alpha$ conjugate for the treatment of ovarian cancer. <i>Journal of Controlled Release</i> , <b>2016</b> , 236, 79-89	11.7	16
108	The mitochondrial calcium uniporter regulates breast cancer progression via HIF-1 $\alpha$ . <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 569-85	12	155
107	Melanoma targeting with [Tc(N)(PNP3)]-labeled $\beta$ -melanocyte stimulating hormone peptide analogs: Effects of cyclization on the radiopharmaceutical properties. <i>Nuclear Medicine and Biology</i> , <b>2016</b> , 43, 788-801	2.1	8
106	Reverse immunoediting: When immunity is edited by antigen. <i>Immunology Letters</i> , <b>2016</b> , 175, 16-20	4.1	15
105	Genome-wide association between YAP/TAZ/TEAD and $\beta$ -catenin at enhancers drives oncogenic growth. <i>Nature Cell Biology</i> , <b>2015</b> , 17, 1218-27	23.4	569
104	Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. <i>Immunology</i> , <b>2015</b> , 146, 33-49	7.8	5
103	Folic acid-conjugated europium complexes as luminescent probes for selective targeting of cancer cells. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 2003-14	8.3	30
102	Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. <i>Oncoscience</i> , <b>2015</b> , 2, 373-81	0.8	13
101	A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts. <i>Oncotarget</i> , <b>2015</b> , 6, 4126-43	3.3	18
100	Hyaluronic Acid as a Protein Polymeric Carrier: An Overview and a Report on Human Growth Hormone. <i>Current Drug Targets</i> , <b>2015</b> , 16, 1503-11	3	8
99	Metabolic control of YAP and TAZ by the mevalonate pathway. <i>Nature Cell Biology</i> , <b>2014</b> , 16, 357-66	23.4	487
98	Novel [99mTc(III)(PS) <sub>2</sub> (Ln)] mixed-ligand compounds (PS = phosphino-thiolate; L = dithiocarbamate) useful in design and development of Tc(III)-based agents: synthesis, in vitro, and ex vivo biodistribution studies. <i>Journal of Medicinal Chemistry</i> , <b>2014</b> , 57, 8960-70	8.3	6
97	[99mTc(N)PNP]-scaffold for SPECT of multidrug resistance: Early in-vitro study. <i>Nuclear Medicine and Biology</i> , <b>2014</b> , 41, 618	2.1	

96	Magneto-plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging. <i>Small</i> , <b>2014</b> , 10, 2476-86	11	130
95	In vivo fate of avidin-nucleic acid nanoassemblies as multifunctional diagnostic tools. <i>ACS Nano</i> , <b>2014</b> , 8, 175-87	16.7	30
94	Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. <i>PLoS ONE</i> , <b>2014</b> , 9, e112240	3.7	10
93	PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. <i>PLoS ONE</i> , <b>2014</b> , 9, e109427	3.7	52
92	Magneto-Plasmonic Au-Fe Alloy Nanoparticles Designed for Multimodal SERS-MRI-CT Imaging. <i>Small</i> , <b>2014</b> , 10, 3823-3823	11	4
91	Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. <i>Molecular Cell</i> , <b>2014</b> , 56, 617-29	17.6	105
90	Functional avidity-driven activation-induced cell death shapes CTL immunodominance. <i>Journal of Immunology</i> , <b>2014</b> , 193, 4704-11	5.3	6
89	Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. <i>EMBO Molecular Medicine</i> , <b>2014</b> , 6, 99-119	12	108
88	Inhibition of growth and induction of apoptosis in human lung cancer cells by Br-oxph. <i>Genetika</i> , <b>2014</b> , 46, 1-10	0.6	0
87	Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. <i>Gastroenterology</i> , <b>2013</b> , 145, 1323-33	13.3	185
86	Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1261-9	2.8	24
85	Survivin expression impacts prognostically on NSCLC but not SCLC. <i>Lung Cancer</i> , <b>2013</b> , 79, 180-6	5.9	26
84	A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2223-32	7.5	42
83	Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). <i>PLoS ONE</i> , <b>2013</b> , 8, e80456	3.7	16
82	HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. <i>Oncotarget</i> , <b>2013</b> , 4, 1293-308	3.3	94
81	SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. <i>Nature</i> , <b>2012</b> , 487, 380-4	50.4	180
80	Amniotic fluid stem cells restore the muscle cell niche in a HSA-Cre, Smn(F7/F7) mouse model. <i>Stem Cells</i> , <b>2012</b> , 30, 1675-84	5.8	56
79	Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 931952		23

78	IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4080-91	12.9	11
77	Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, 527-39	5.7	49
76	Optical and multimodal peptide-based probes for in vivo molecular imaging. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2012</b> , 12, 476-99	2.2	10
75	Feasibility study of the proton yield from the reaction $D(3He,p)4He$ as a possible tool for radiotherapy treatment. <i>Journal of Physics: Conference Series</i> , <b>2012</b> , 398, 012029	0.3	
74	The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. <i>Cell</i> , <b>2011</b> , 147, 759-72	56.2	886
73	A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. <i>Cancer Cell</i> , <b>2011</b> , 20, 79-91	24.3	209
72	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. <i>Blood</i> , <b>2011</b> , 118, 2254-65	2.2	280
71	Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 1639-45	7.4	4
70	Immunotherapy for EBV-associated malignancies. <i>International Journal of Hematology</i> , <b>2011</b> , 93, 281-293.	3.3	26
69	Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study. <i>Journal of Urology</i> , <b>2011</b> , 185, 445-9	2.5	71
68	Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. <i>Journal of Immunology</i> , <b>2010</b> , 184, 5895-902	5.3	37
67	Impact of E-chain cytokines on EBV-specific T cell cultures. <i>Journal of Translational Medicine</i> , <b>2010</b> , 8, 121	8.5	4
66	A MicroRNA targeting dicer for metastasis control. <i>Cell</i> , <b>2010</b> , 141, 1195-207	56.2	551
65	Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. <i>International Reviews of Immunology</i> , <b>2010</b> , 29, 371-402	4.6	36
64	The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. <i>Haematologica</i> , <b>2010</b> , 95, 1769-77	6.6	75
63	Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. <i>Cancer Research</i> , <b>2009</b> , 69, 9385-94	10.1	47
62	Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , <b>2009</b> , 9, 113-31	2.2	27
61	Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 1358-64	7.5	17

60	The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. <i>Nature Cell Biology</i> , <b>2009</b> , 11, 133-42	23.4	139
59	Biokinetic and dosimetric studies of <sup>188</sup> Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. <i>Nuclear Medicine and Biology</i> , <b>2009</b> , 36, 693-701	2.1	15
58	Synthesis and preliminary in vitro biological evaluation of 4-[(4-hydroxyphenyl)sulfanyl]but-3-en-2-one, a 4-mercaptophenol derivative designed as a novel bifunctional antimelanoma agent. <i>Journal of Medicinal Chemistry</i> , <b>2009</b> , 52, 4973-6	8.3	11
57	A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. <i>Cell</i> , <b>2009</b> , 137, 87-98	56.2	629
56	Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. <i>Nuclear Medicine and Biology</i> , <b>2009</b> , 36, 525-33	2.1	21
55	Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. <i>Human Pathology</i> , <b>2009</b> , 40, 1600-10	3.7	44
54	Glutathione transferases as targets for cancer therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2009</b> , 9, 763-77	2.2	64
53	In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes. <i>Biochemical Pharmacology</i> , <b>2008</b> , 76, 784-95	6	16
52	Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. <i>Expert Opinion on Biological Therapy</i> , <b>2008</b> , 8, 1265-94	5.4	34
51	A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3598-606	12.9	77
50	Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. <i>Journal of Immunology</i> , <b>2008</b> , 180, 7736-46	5.3	69
49	Novel types of carborane-carrier hyaluronan derivatives via "click chemistry". <i>Macromolecular Bioscience</i> , <b>2008</b> , 8, 670-81	5.5	31
48	Simulations and tests for metabolic radiotherapy with <sup>188</sup> Re. <i>Nuclear Physics, Section B, Proceedings Supplements</i> , <b>2007</b> , 172, 303-307		
47	<sup>188</sup> Rhenium-induced cell death and apoptosis in a panel of tumor cell lines. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , <b>2007</b> , 571, 471-474	1.2	5
46	A YAP camera for the biodistribution of <sup>188</sup> Re conjugated with Hyaluronic-Acid in <i>in vivo</i> systems. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , <b>2007</b> , 571, 484-487	1.2	4
45	T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy. <i>Expert Opinion on Biological Therapy</i> , <b>2007</b> , 7, 893-906	5.4	13
44	Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy. <i>Biomacromolecules</i> , <b>2007</b> , 8, 552-9	6.9	57
43	Preliminary study of metabolic radiotherapy with <sup>188</sup> Re via small animal imaging. <i>Nuclear Physics, Section B, Proceedings Supplements</i> , <b>2006</b> , 150, 411-416		4



42	Identifying type Vicenza von Willebrand disease. <i>Translational Research</i> , <b>2006</b> , 147, 96-102		16
41	Wet sol-gel derived silica for controlled release of proteins. <i>Journal of Controlled Release</i> , <b>2006</b> , 116, 295-303	11.7	44
40	Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 1717-22	7.5	50
39	Bioavailability of 99mTc-Ha-paclitaxel complex [99mTc-ONCOFID-P] in mice using four different administration routes. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2006</b> , 49, 939-950	1.9	16
38	The scaffold protein Cybr is required for cytokine-modulated trafficking of leukocytes in vivo. <i>Molecular and Cellular Biology</i> , <b>2006</b> , 26, 5249-58	4.8	16
37	Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters. <i>Journal of Immunology</i> , <b>2006</b> , 176, 1999-2006	5.3	14
36	Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis. <i>Human Pathology</i> , <b>2006</b> , 37, 16-22	3.7	15
35	HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 207-15	2.8	74
34	Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 1608-17	12.9	57
33	A large number of T lymphocytes recognize Moloney-murine leukemia virus-induced antigens, but a few mediate long-lasting tumor immunosurveillance. <i>Journal of Immunology</i> , <b>2005</b> , 174, 5398-406	5.3	8
32	Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 6629-34	11.5	68
31	Quantitative imaging of the T cell antitumor response by positron-emission tomography. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 1232-7	11.5	130
30	Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. <i>Journal of Immunology</i> , <b>2003</b> , 171, 5172-9	5.3	16
29	In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 3893-901	5.6	15
28	Effect of antiadhesive agents on peritoneal carcinomatosis in an experimental model. <i>British Journal of Surgery</i> , <b>2003</b> , 90, 66-71	5.3	32
27	CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes. <i>Journal of Immunology</i> , <b>2003</b> , 171, 4528-38	5.3	19
26	The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. <i>Cancer Research</i> , <b>2003</b> , 63, 2158-63	10.1	30
25	Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. <i>Gene Therapy</i> , <b>2002</b> , 9, 867-78	4	70

24	Some Patients with Antiphospholipid Syndrome Express hitherto Undescribed Antibodies to Cardiolipin-binding Proteins. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 85, 57-62	7	33
23	CTL Analysis for Tumor Vaccines. <i>Methods in Molecular Medicine</i> , <b>2000</b> , 29, 123-32		
22	A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement. <i>BMJ: British Medical Journal</i> , <b>1999</b> , 319, 1054-9		468
21	[Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. <i>Lupus</i> , <b>1999</b> , 8, 121-6	2.6	18
20	Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases. <i>British Journal of Cancer</i> , <b>1999</b> , 79, 1067-73	8.7	2
19	DNA-based vaccination against tumors expressing the P1A antigen. <i>Methods</i> , <b>1999</b> , 19, 187-90	4.6	11
18	Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach. <i>Journal of Virology</i> , <b>1999</b> , 73, 2280-7	6.6	13
17	DNA immunization of mice against SIVmac239 Gag and Env using Rev-independent expression plasmids. <i>AIDS Research and Human Retroviruses</i> , <b>1998</b> , 14, 83-90	1.6	19
16	Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity. <i>British Journal of Cancer</i> , <b>1998</b> , 77, 656-62	8.7	11
15	DNA immunization in mice against virus-induced tumor antigens. <i>Advances in Experimental Medicine and Biology</i> , <b>1998</b> , 451, 311-4	3.6	1
14	CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. <i>Human Gene Therapy</i> , <b>1997</b> , 8, 1451-8	4.8	32
13	The human T-cell lymphotropic virus type 1 Tof protein contains a bipartite nuclear localization signal that is able to functionally replace the amino-terminal domain of Rex. <i>Journal of Virology</i> , <b>1997</b> , 71, 75-83	6.6	38
12	Inflammatory polyarthropathy and bone remodeling in HTLV-I Tax-transgenic mice. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1997</b> , 14, 272-80		13
11	Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 218, 344-51	3.4	34
10	CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 226, 769-76	3.4	12
9	Membrane form of TNF alpha induces both cell lysis and apoptosis in susceptible target cells. <i>Cellular Immunology</i> , <b>1996</b> , 171, 102-10	4.4	32
8	Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. <i>International Journal of Cancer</i> , <b>1996</b> , 65, 847-51	7.5	10
7	Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). <i>International Journal of Cancer</i> , <b>1995</b> , 61, 355-62	7.5	7

6	Inhibition of protein tyrosine phosphorylation prevents T-cell-mediated cytotoxicity. <i>Cellular Immunology</i> , <b>1994</b> , 159, 294-305	4.4	10
5	Synergistic effect of extracellular adenosine 5'-triphosphate and tumor necrosis factor on DNA degradation. <i>Cellular Immunology</i> , <b>1993</b> , 152, 110-9	4.4	9
4	Therapeutical effect of 4'-deoxy-4'-iododoxorubicin-loaded LAK cells in mice bearing lung metastases. <i>Pharmacological Research</i> , <b>1992</b> , 26 Suppl 2, 124-5	10.2	1
3	Inhibition of CTL-line lysis after gangliosides treatment. <i>Pharmacological Research</i> , <b>1992</b> , 26 Suppl 2, 190-1	10.2	
2	Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. <i>Cancer Immunology, Immunotherapy</i> , <b>1992</b> , 35, 27-32	7.4	6
1	Interaction of lymphokine-activated killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis. <i>Journal of Experimental Medicine</i> , <b>1989</b> , 170, 665-77	16.6	41